Experience with thoracic aortic stent-grafting at the Royal Brisbane and Women’s Hospital: outcomes from the first decade

Hoenig, Michel R., Jenkins, Jason, Boyne, Nicholas, Kruger, Allan and Walker, Philip J. (2012) Experience with thoracic aortic stent-grafting at the Royal Brisbane and Women’s Hospital: outcomes from the first decade. World Journal of Cardiovascular Surgery, 2 3: 29-39. doi:10.4236/wjcs.2012.23009

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Hoenig, Michel R.
Jenkins, Jason
Boyne, Nicholas
Kruger, Allan
Walker, Philip J.
Title Experience with thoracic aortic stent-grafting at the Royal Brisbane and Women’s Hospital: outcomes from the first decade
Journal name World Journal of Cardiovascular Surgery   Check publisher's open access policy
ISSN 2164-3202
2164-3210
Publication date 2012-09
Year available 2012
Sub-type Article (original research)
DOI 10.4236/wjcs.2012.23009
Open Access Status DOI
Volume 2
Issue 3
Start page 29
End page 39
Total pages 11
Place of publication Irvine, CA, United States
Publisher World Journal of Cardiovascular Surgery
Collection year 2013
Language eng
Formatted abstract
Objectives: To describe thoracic endovascular aortic repair (TEVAR) outcomes at the Royal Brisbane and Women’s Hospital between 2001-2010. Design: Prospective cohort study. Results: We successfully treated 95 of 97 patients for a 98% procedural success rate. Of the treated patients, 68 (72%) were males and mean age was 61 ± 17 years. Average follow up was 3.6 ± 2.0 years. Pathologies treated were: dissection (n = 35), aneurysmal disease (n = 32), traumatic disease (n = 19), coarctation (n = 5) and miscellaneous (n = 4). There was one peri-procedural myocardial infarction. Renal complications occurred in 7 patients (3 with doubling creatinine and 4 requiring temporary renal replacement therapy). Stroke occurred in 2 patients and paresis in 2 patients (permanent in one). Six patients died during index hospitalization and 17 deaths occurred during follow-up, 2 of which were confirmed secondary to aortic pathology. Age (HR 1.08 per year, p < 0.01) and ASA class (HR 2.2 per class, p = 0.02) were independently associated with mortality. There were 25 re-interventions in 22 patients. Eighteen of these re-interventions in 16 patients were related to the management of complications of TEVAR of which 13 were for endoleaks; eight type I, four type II, one type III. Conclusion: TEVAR can be used to treat thoracic aortic pathology but questions remain regarding long-term durability.
Keyword Aorta
Stents
Surgery
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2013 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: Google Scholar Search Google Scholar
Created: Tue, 08 Jan 2013, 13:09:07 EST by Professor Philip Walker on behalf of Surgery - Royal Brisbane and Women's Hospital